Anzeige
Meldung des Tages: Early Bird Special: Ad-hoc im Schatten einer milliardenschweren Entscheidung

BioVersys News

Aktie
WKN:  A410LA ISIN:  CH0210362643 Branche:  Biotechnologie Land:  Schweiz
28,40 CHF
-1,10 CHF
-3,73%
30,994 € 30.04.26
Depot/Watchlist
Marktkapitalisierung *
155,52 Mio. €
Streubesitz
24,62%
KGV
-
Index-Zuordnung
-

BioVersys News

30.04.26 - EQS
BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
BioVersys AG / Key word(s): AGMEGM BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders 30.04.2026 / 19:00 CET/CEST Basel, ...
22.04.26 - EQS
BioVersys completes BV100 Phase 1 clinical trial in China
BioVersys AG / Key word(s): Study/Study results BioVersys completes BV100 Phase 1 clinical trial in China 22-Apr-2026 / 07:00 CET/CEST Release of an ad hoc announcement ...
16.04.26 - EQS
BioVersys announces first patient first visit in HABP/VABP pivotal Phase 3 RIV-TARGET trial of BV100
BioVersys AG / Key word(s): Study BioVersys announces first patient first visit in HABP/VABP pivotal Phase 3 RIV-​TARGET trial of BV100 16-Apr-2026 / 07:00 CET/CEST Release of ...
15.04.26 - EQS
BioVersys to present data on clinical and preclinical pipeline programs at ESCMID Global 2026
BioVersys AG / Key word(s): Conference BioVersys to present data on clinical and preclinical pipeline programs at ESCMID Global 2026 15.04.2026 / 07:00 CET/CEST Basel, ...
13.04.26 - EQS
Data published in Nature Communications highlights unique Mechanism of Action of Alpibectir in combination with Ethionamide (AlpE)
BioVersys AG / Key word(s): Scientific publication Data published in Nature Communications highlights unique Mechanism of Action of Alpibectir in combination with Ethionamide ...
07.04.26 - EQS
BioVersys Issues Invitation to its 2026 Annual General Meeting of Shareholders
BioVersys AG / Key word(s): AGMEGM BioVersys Issues Invitation to its 2026 Annual General Meeting of Shareholders 07-Apr-2026 / 07:00 CET/CEST Release of an ad hoc ...
02.04.26 - EQS
BioVersys Appoints Anca Cighi as Head of Investor Relations and Communications
BioVersys AG / Key word(s): Personnel BioVersys Appoints Anca Cighi as Head of Investor Relations and Communications 02.04.2026 / 07:00 CET/CEST Basel, Switzerland. April ...
31.03.26 - EQS
BioVersys strengthens Ansamycin platform and NTM research through collaboration and license agreement with Hackensack Meridian Health
BioVersys AG / Key word(s): Agreement BioVersys strengthens Ansamycin platform and NTM research through collaboration and license agreement with Hackensack Meridian ...
18.03.26 - EQS
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
BioVersys AG / Key word(s): Annual Results BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025 18-March-2026 / 07:00 CET/CEST Release of an ...
16.03.26 - EQS
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
BioVersys AG / Key word(s): Regulatory Admission/Study BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start 16-March-2026 / 07:00 ...
12.03.26 - EQS
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
BioVersys AG / Key word(s): Study BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis 12-March-2026 / 07:00 CET/CEST ...
05.03.26 - EQS
BioVersys to Report its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call
BioVersys AG / Key word(s): Annual Results BioVersys to Report its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call 05.03.2026 / 07:00 ...
04.03.26 - EQS
BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy
BioVersys AG / Key word(s): Scientific publication BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy ...
19.02.26 - EQS
BioVersys and partners’ phase 2a tuberculosis trial results published in New England Journal of Medicine
BioVersys AG / Key word(s): Scientific publication BioVersys and partners’ phase 2a tuberculosis trial results published in New England Journal of Medicine 19.02.2026 / 07:17 ...
11.12.25 - EQS
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
BioVersys AG / Key word(s): Study BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update 11-Dec-2025 / 07:00 CET/CEST Release of an ad hoc ...
10.11.25 - EQS
BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network
BioVersys AG / Key word(s): Study/Funds BioVersys BV100 Phase 2B to be conducted via Wellcome Funded Trial Network 10-Nov-2025 / 07:00 CET/CEST Release of an ad hoc ...
06.11.25 - EQS
Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA
BioVersys AG / Key word(s): Study Bioversys ANNOUNCES FIRST SUBJECTS DOSED IN PHASE 1 CLINICAL TRIAL OF BV100 in CHInA 06-Nov-2025 / 07:00 CET/CEST Release of ...
05.11.25 - EQS
Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york
BioVersys AG / Key word(s): Conference Bioversys to Present at Stifel 2025 Annual Healthcare Conference in New york 05.11.2025 / 07:00 CET/CEST
03.11.25 - EQS
Bioversys announces appointment of anti-infective expert Dr. Daniel Ritz as Chief Scientific Officer and retirement of Dr. Sergio Lociuro
BioVersys AG / Key word(s): Personnel Bioversys announces appointment of anti-​infective expert Dr. Daniel Ritz as Chief Scientific Officer and retirement of Dr. Sergio Lociuro ...
10.09.25 - EQS
Bioversys reports corporate highlights and key financials for the first half 2025
BioVersys AG / Key word(s): Half Year Results Bioversys reports corporate highlights and key financials for the first half 2025 10-Sep-2025 / 07:00 CET/CEST Release of an ad hoc ...

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »
Anzeige

Aktie im Fokus

Mit Graphen gegen jede Abwehr
Plaid Technologies
0,396 €
+7,03%
Plaid Technologies Chart
Die Zukunft der Drohnen ist da
Mehr zur Aktie »